EXPORT LICENSE

NRC FORM 250



United States of America

Nuclear Regulatory Commission Washington, D.C. 20555

NRC LICENSE NO.: XMAT422/04

Page 1 of 13

NRC DOCKET NO.: 11005997

LICENSE EXPIRES: December 31, 2025

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE	ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
Cambridge Isotope Laboratories Inc. 50 Frontage Road Andover, MA 01810	See following page(s)
Attn: Rebecca Dabkowski	
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)	OTHER U.S. PARTY(IES) TO EXPORT
See following page(s)	None
APPLICANT'S REFERENCE: Appl dated 07/29/2020	ULTIMATE DESTINATION: China

QUANTITY(IES)

DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)

This license is amended to: 1) increase the total amount of the various deuterium compounds from 10,000 kgs to 15,000 kgs; 2) update the licensee point of contact; 3) extend the expiration date from May 31, 2024 to December 31, 2025; 4) update the lists of the Ultimate and Intermediate Consignees by adding additional parties and changing addresses; and 5) update the addresses to Other U.S. Parties to Export.

The licensee is authorized to export a cumulative total of 15,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT422.

CONDITION: A license amendment request is required for the addition of intermediate consignees not listed on this export license.

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.


This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE

David Skeen Skeen Skeen Skeen Skeen Skeen Oate: 2021.09.28 09:58:09 0-0400'

NAME AND TITLE: David L. Skeen, Deputy Director Office of International Programs

DATE OF ISSUANCE: September 28, 2021





(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10. China

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11. China

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12. China

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13. China

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


14. China


(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


15. China


(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


16. China













(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)




(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)





(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)


INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. China
(for distribution to ultimate consignees)









(101 distribution to distribute someignoss)

30. China

(for distribution to ultimate consignees)

OTHER U.S. PARTY(IES) TO EXPORT:

- Cambridge Isotope Laboratories, Inc. 6 Highwood Drive Tewksbury, MA 01876 (supplier)
- 2. Cambridge Isotope Separations 1689 Burnett Drive Xenia, OH 45385

(supplier)